Cannabis shows promise for IBD symptoms in the lab but has not yet delivered in clinical trials | Research

The takeaway

Despite strong preclinical evidence that cannabinoids improve colitis in animal models, the few clinical trials in human IBD have shown no meaningful benefit, with the largest trial limited by poor THC tolerance.

IBD patients considering cannabis, gastroenterologists, and researchers designing cannabinoid clinical trials for inflammatory conditions.

Lab success, clinical gap

What the researchers found

In animal models, both exogenous cannabinoids and modulation of the endocannabinoid system consistently improved colitis. However, this did not translate to human IBD in the few clinical trials conducted. The largest study was limited by poor medication tolerance due to THC content. Cannabis use surveys show patients report symptom improvements, but controlled evidence is lacking.

Why it matters

IBD patients are already using cannabis for symptom relief based on anecdotal reports, but the disconnect between strong animal data and weak human trial results highlights a critical evidence gap. Understanding why preclinical promise has not translated to clinical benefit is essential.

The numbers in context

The largest clinical trial was limited by poor THC tolerance. Cannabis use surveys show IBD patients commonly report improvements in pain, appetite, and diarrhea. Preclinical models using pharmacological receptor agonists, genetic knockouts, and enzyme inhibitors largely showed improvements.

How the study worked

Narrative review synthesizing preclinical studies (chemical colitis models, genetic knockout models, enzyme inhibition studies), clinical surveys of cannabis use in IBD, and the limited clinical trial data available.

What this study cannot tell us

Very few clinical trials have been conducted in human IBD. Animal colitis models (mainly chemical-induced) do not perfectly represent human Crohn's or ulcerative colitis. Survey data on cannabis use is subject to recall and reporting bias.

How to read the evidence

Rated moderate because the review synthesizes a large body of preclinical evidence and limited clinical data, identifying a clear translational gap.

When this study was published

Published in 2019. Additional clinical trials for cannabinoids in IBD may have been completed since.

The bigger picture

IBD represents a common pattern in cannabinoid research: promising animal data, strong patient interest, widespread self-medication, but minimal controlled clinical evidence. The THC tolerance issue suggests CBD-focused or alternative delivery approaches may be needed.

Questions still open

Would CBD-only formulations avoid the tolerance issues of THC? Are there specific IBD subtypes more likely to respond? Could endocannabinoid system modulation (enzyme inhibitors) work better than direct cannabinoid administration?

Common questions

Does cannabis help IBD?

Animal studies consistently show benefit, and many patients report symptom relief. However, the few controlled clinical trials in humans have not demonstrated meaningful improvement, with the largest limited by THC side effects.

Why doesn't the animal evidence translate to humans?

The review suggests several factors: animal models use chemical-induced colitis that may not match human IBD, THC tolerance limits dosing in humans, and the endocannabinoid system may need to be targeted differently in clinical settings.

Should IBD patients use cannabis?

The controlled clinical evidence does not currently support it, despite positive anecdotal reports. The review highlights the need for better-designed trials, possibly with CBD-focused or alternative formulations.

Read the original research

Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease?

Journal of Crohn's & colitis, 13(4), 525-535

View on PubMed ↗Publisher’s paper ↗

Citation

Ambrose, Tim; Simmons, Alison. (2019). Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease?. Journal of Crohn's & colitis, 13(4), 525-535. https://doi.org/10.1093/ecco-jcc/jjy185